(Wisconsin) Congressman Glenn Grothman recently introduced legislation to help increase competition in the insulin market, expand availability to affordable insulin products and lower costs to patients who depend on insulin. The legislation would waive interchangeability requirements of insulin products granted biosimilar approval by the Food and Drug Administration. That would enable pharmacists to dispense and patients to choose which biosimilar product works best for their individual needs instead of being forced to pay top-dollar for brand name insulin, or a reference product. FDA-approved biosimilars could save patients and the health care system anywhere from $54 to $250 billion over their first 10 years on the market.
Legislation Seeks To Lower Insulin Costs
